Global Targeting p53 Cancer Therapies Market Research Report 2023

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

The essence of p53-targeted therapy is to regain the "tumor suppressor function" of the mutated p53 protein, or indirectly protect the "tumor suppressor function" of p53 by inhibiting other targets that can inhibit the wild-type p53 protein.

According to QYResearch’s new survey, global Targeting p53 Cancer Therapies market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Targeting p53 Cancer Therapies market research.

Key manufacturers engaged in the Targeting p53 Cancer Therapies industry include Sibiono GeneTech, Kartos Therapeutics, SynerGene Therapeutics, MultiVir, Rain Oncology, Alieron Therapeutics, Aprea Therapeutics, Ascentage Pharma and Jc (Wuxi) Company, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Targeting p53 Cancer Therapies were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Targeting p53 Cancer Therapies market and estimated to attract more attentions from industry insiders and investors.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Targeting p53 Cancer Therapies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
    Sibiono GeneTech
    Kartos Therapeutics
    SynerGene Therapeutics
    MultiVir
    Rain Oncology
    Alieron Therapeutics
    Aprea Therapeutics
    Ascentage Pharma
    Jc (Wuxi) Company

Segment by Type
    Small Molecule Drugs
    Immunotherapy
    Gene Therapy
    Others

Segment by Application
    Hospital
    Clinic
    Others

Consumption by Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Southeast Asia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

The Targeting p53 Cancer Therapies report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

 1 Targeting p53 Cancer Therapies Market Overview
    1.1 Product Overview and Scope of Targeting p53 Cancer Therapies
    1.2 Targeting p53 Cancer Therapies Segment by Type
        1.2.1 Global Targeting p53 Cancer Therapies Market Value Comparison by Type (2023-2029)
        1.2.2 Small Molecule Drugs
        1.2.3 Immunotherapy
        1.2.4 Gene Therapy
        1.2.5 Others
    1.3 Targeting p53 Cancer Therapies Segment by Application
        1.3.1 Global Targeting p53 Cancer Therapies Market Value by Application: (2023-2029)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Global Targeting p53 Cancer Therapies Market Size Estimates and Forecasts
        1.4.1 Global Targeting p53 Cancer Therapies Revenue 2018-2029
        1.4.2 Global Targeting p53 Cancer Therapies Sales 2018-2029
        1.4.3 Global Targeting p53 Cancer Therapies Market Average Price (2018-2029)
    1.5 Assumptions and Limitations

 2 Targeting p53 Cancer Therapies Market Competition by Manufacturers
    2.1 Global Targeting p53 Cancer Therapies Sales Market Share by Manufacturers (2018-2023)
    2.2 Global Targeting p53 Cancer Therapies Revenue Market Share by Manufacturers (2018-2023)
    2.3 Global Targeting p53 Cancer Therapies Average Price by Manufacturers (2018-2023)
    2.4 Global Targeting p53 Cancer Therapies Industry Ranking 2021 VS 2022 VS 2023
    2.5 Global Key Manufacturers of Targeting p53 Cancer Therapies, Manufacturing Sites & Headquarters
    2.6 Global Key Manufacturers of Targeting p53 Cancer Therapies, Product Type & Application
    2.7 Targeting p53 Cancer Therapies Market Competitive Situation and Trends
        2.7.1 Targeting p53 Cancer Therapies Market Concentration Rate
        2.7.2 The Global Top 5 and Top 10 Largest Targeting p53 Cancer Therapies Players Market Share by Revenue
        2.7.3 Global Targeting p53 Cancer Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

 3 Targeting p53 Cancer Therapies Retrospective Market Scenario by Region
    3.1 Global Targeting p53 Cancer Therapies Market Size by Region: 2018 Versus 2022 Versus 2029
    3.2 Global Targeting p53 Cancer Therapies Global Targeting p53 Cancer Therapies Sales by Region: 2018-2029
        3.2.1 Global Targeting p53 Cancer Therapies Sales by Region: 2018-2023
        3.2.2 Global Targeting p53 Cancer Therapies Sales by Region: 2024-2029
    3.3 Global Targeting p53 Cancer Therapies Global Targeting p53 Cancer Therapies Revenue by Region: 2018-2029
        3.3.1 Global Targeting p53 Cancer Therapies Revenue by Region: 2018-2023
        3.3.2 Global Targeting p53 Cancer Therapies Revenue by Region: 2024-2029
    3.4 North America Targeting p53 Cancer Therapies Market Facts & Figures by Country
        3.4.1 North America Targeting p53 Cancer Therapies Market Size by Country: 2018 VS 2022 VS 2029
        3.4.2 North America Targeting p53 Cancer Therapies Sales by Country (2018-2029)
        3.4.3 North America Targeting p53 Cancer Therapies Revenue by Country (2018-2029)
        3.4.4 United States
        3.4.5 Canada
    3.5 Europe Targeting p53 Cancer Therapies Market Facts & Figures by Country
        3.5.1 Europe Targeting p53 Cancer Therapies Market Size by Country: 2018 VS 2022 VS 2029
        3.5.2 Europe Targeting p53 Cancer Therapies Sales by Country (2018-2029)
        3.5.3 Europe Targeting p53 Cancer Therapies Revenue by Country (2018-2029)
        3.5.4 Germany
        3.5.5 France
        3.5.6 U.K.
        3.5.7 Italy
        3.5.8 Russia
    3.6 Asia Pacific Targeting p53 Cancer Therapies Market Facts & Figures by Country
        3.6.1 Asia Pacific Targeting p53 Cancer Therapies Market Size by Country: 2018 VS 2022 VS 2029
        3.6.2 Asia Pacific Targeting p53 Cancer Therapies Sales by Country (2018-2029)
        3.6.3 Asia Pacific Targeting p53 Cancer Therapies Revenue by Country (2018-2029)
        3.6.4 China
        3.6.5 Japan
        3.6.6 South Korea
        3.6.7 India
        3.6.8 Australia
        3.6.9 China Taiwan
        3.6.10 Southeast Asia
    3.7 Latin America Targeting p53 Cancer Therapies Market Facts & Figures by Country
        3.7.1 Latin America Targeting p53 Cancer Therapies Market Size by Country: 2018 VS 2022 VS 2029
        3.7.2 Latin America Targeting p53 Cancer Therapies Sales by Country (2018-2029)
        3.7.3 Latin America Targeting p53 Cancer Therapies Revenue by Country (2018-2029)
        3.7.4 Mexico
        3.7.5 Brazil
        3.7.6 Argentina
    3.8 Middle East and Africa Targeting p53 Cancer Therapies Market Facts & Figures by Country
        3.8.1 Middle East and Africa Targeting p53 Cancer Therapies Market Size by Country: 2018 VS 2022 VS 2029
        3.8.2 Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2018-2029)
        3.8.3 Middle East and Africa Targeting p53 Cancer Therapies Revenue by Country (2018-2029)
        3.8.4 Turkey
        3.8.5 Saudi Arabia
        3.8.6 UAE

 4 Segment by Type
    4.1 Global Targeting p53 Cancer Therapies Sales by Type (2018-2029)
        4.1.1 Global Targeting p53 Cancer Therapies Sales by Type (2018-2023)
        4.1.2 Global Targeting p53 Cancer Therapies Sales by Type (2024-2029)
        4.1.3 Global Targeting p53 Cancer Therapies Sales Market Share by Type (2018-2029)
    4.2 Global Targeting p53 Cancer Therapies Revenue by Type (2018-2029)
        4.2.1 Global Targeting p53 Cancer Therapies Revenue by Type (2018-2023)
        4.2.2 Global Targeting p53 Cancer Therapies Revenue by Type (2024-2029)
        4.2.3 Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2018-2029)
    4.3 Global Targeting p53 Cancer Therapies Price by Type (2018-2029)

 5 Segment by Application
    5.1 Global Targeting p53 Cancer Therapies Sales by Application (2018-2029)
        5.1.1 Global Targeting p53 Cancer Therapies Sales by Application (2018-2023)
        5.1.2 Global Targeting p53 Cancer Therapies Sales by Application (2024-2029)
        5.1.3 Global Targeting p53 Cancer Therapies Sales Market Share by Application (2018-2029)
    5.2 Global Targeting p53 Cancer Therapies Revenue by Application (2018-2029)
        5.2.1 Global Targeting p53 Cancer Therapies Revenue by Application (2018-2023)
        5.2.2 Global Targeting p53 Cancer Therapies Revenue by Application (2024-2029)
        5.2.3 Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2018-2029)
    5.3 Global Targeting p53 Cancer Therapies Price by Application (2018-2029)

 6 Key Companies Profiled
    6.1 Sibiono GeneTech
        6.1.1 Sibiono GeneTech Corporation Information
        6.1.2 Sibiono GeneTech Description and Business Overview
        6.1.3 Sibiono GeneTech Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2018-2023)
        6.1.4 Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio
        6.1.5 Sibiono GeneTech Recent Developments/Updates
    6.2 Kartos Therapeutics
        6.2.1 Kartos Therapeutics Corporation Information
        6.2.2 Kartos Therapeutics Description and Business Overview
        6.2.3 Kartos Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2018-2023)
        6.2.4 Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio
        6.2.5 Kartos Therapeutics Recent Developments/Updates
    6.3 SynerGene Therapeutics
        6.3.1 SynerGene Therapeutics Corporation Information
        6.3.2 SynerGene Therapeutics Description and Business Overview
        6.3.3 SynerGene Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2018-2023)
        6.3.4 SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio
        6.3.5 SynerGene Therapeutics Recent Developments/Updates
    6.4 MultiVir
        6.4.1 MultiVir Corporation Information
        6.4.2 MultiVir Description and Business Overview
        6.4.3 MultiVir Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2018-2023)
        6.4.4 MultiVir Targeting p53 Cancer Therapies Product Portfolio
        6.4.5 MultiVir Recent Developments/Updates
    6.5 Rain Oncology
        6.5.1 Rain Oncology Corporation Information
        6.5.2 Rain Oncology Description and Business Overview
        6.5.3 Rain Oncology Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2018-2023)
        6.5.4 Rain Oncology Targeting p53 Cancer Therapies Product Portfolio
        6.5.5 Rain Oncology Recent Developments/Updates
    6.6 Alieron Therapeutics
        6.6.1 Alieron Therapeutics Corporation Information
        6.6.2 Alieron Therapeutics Description and Business Overview
        6.6.3 Alieron Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2018-2023)
        6.6.4 Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio
        6.6.5 Alieron Therapeutics Recent Developments/Updates
    6.7 Aprea Therapeutics
        6.6.1 Aprea Therapeutics Corporation Information
        6.6.2 Aprea Therapeutics Description and Business Overview
        6.6.3 Aprea Therapeutics Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2018-2023)
        6.4.4 Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio
        6.7.5 Aprea Therapeutics Recent Developments/Updates
    6.8 Ascentage Pharma
        6.8.1 Ascentage Pharma Corporation Information
        6.8.2 Ascentage Pharma Description and Business Overview
        6.8.3 Ascentage Pharma Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2018-2023)
        6.8.4 Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio
        6.8.5 Ascentage Pharma Recent Developments/Updates
    6.9 Jc (Wuxi) Company
        6.9.1 Jc (Wuxi) Company Corporation Information
        6.9.2 Jc (Wuxi) Company Description and Business Overview
        6.9.3 Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales, Revenue and Gross Margin (2018-2023)
        6.9.4 Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio
        6.9.5 Jc (Wuxi) Company Recent Developments/Updates

 7 Industry Chain and Sales Channels Analysis
    7.1 Targeting p53 Cancer Therapies Industry Chain Analysis
    7.2 Targeting p53 Cancer Therapies Key Raw Materials
        7.2.1 Key Raw Materials
        7.2.2 Raw Materials Key Suppliers
    7.3 Targeting p53 Cancer Therapies Production Mode & Process
    7.4 Targeting p53 Cancer Therapies Sales and Marketing
        7.4.1 Targeting p53 Cancer Therapies Sales Channels
        7.4.2 Targeting p53 Cancer Therapies Distributors
    7.5 Targeting p53 Cancer Therapies Customers

 8 Targeting p53 Cancer Therapies Market Dynamics
    8.1 Targeting p53 Cancer Therapies Industry Trends
    8.2 Targeting p53 Cancer Therapies Market Drivers
    8.3 Targeting p53 Cancer Therapies Market Challenges
    8.4 Targeting p53 Cancer Therapies Market Restraints

 9 Research Finding and Conclusion

 10 Methodology and Data Source
    10.1 Methodology/Research Approach
        10.1.1 Research Programs/Design
        10.1.2 Market Size Estimation
        10.1.3 Market Breakdown and Data Triangulation
    10.2 Data Source
        10.2.1 Secondary Sources
        10.2.2 Primary Sources
    10.3 Author List
    10.4 Disclaimer

List of Tables
    Table 1. Global Targeting p53 Cancer Therapies Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global Targeting p53 Cancer Therapies Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global Targeting p53 Cancer Therapies Market Competitive Situation by Manufacturers in 2022
    Table 4. Global Targeting p53 Cancer Therapies Sales (K Units) of Key Manufacturers (2018-2023)
    Table 5. Global Targeting p53 Cancer Therapies Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global Targeting p53 Cancer Therapies Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global Targeting p53 Cancer Therapies Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market Targeting p53 Cancer Therapies Average Price (US$/Unit) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of Targeting p53 Cancer Therapies, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of Targeting p53 Cancer Therapies, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Targeting p53 Cancer Therapies, Product Type & Application
    Table 12. Global Key Manufacturers of Targeting p53 Cancer Therapies, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Targeting p53 Cancer Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeting p53 Cancer Therapies as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Targeting p53 Cancer Therapies Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global Targeting p53 Cancer Therapies Sales by Region (2018-2023) & (K Units)
    Table 18. Global Targeting p53 Cancer Therapies Sales Market Share by Region (2018-2023)
    Table 19. Global Targeting p53 Cancer Therapies Sales by Region (2024-2029) & (K Units)
    Table 20. Global Targeting p53 Cancer Therapies Sales Market Share by Region (2024-2029)
    Table 21. Global Targeting p53 Cancer Therapies Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global Targeting p53 Cancer Therapies Revenue Market Share by Region (2018-2023)
    Table 23. Global Targeting p53 Cancer Therapies Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global Targeting p53 Cancer Therapies Revenue Market Share by Region (2024-2029)
    Table 25. North America Targeting p53 Cancer Therapies Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America Targeting p53 Cancer Therapies Sales by Country (2018-2023) & (K Units)
    Table 27. North America Targeting p53 Cancer Therapies Sales by Country (2024-2029) & (K Units)
    Table 28. North America Targeting p53 Cancer Therapies Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America Targeting p53 Cancer Therapies Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe Targeting p53 Cancer Therapies Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe Targeting p53 Cancer Therapies Sales by Country (2018-2023) & (K Units)
    Table 32. Europe Targeting p53 Cancer Therapies Sales by Country (2024-2029) & (K Units)
    Table 33. Europe Targeting p53 Cancer Therapies Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe Targeting p53 Cancer Therapies Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific Targeting p53 Cancer Therapies Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific Targeting p53 Cancer Therapies Sales by Region (2018-2023) & (K Units)
    Table 37. Asia Pacific Targeting p53 Cancer Therapies Sales by Region (2024-2029) & (K Units)
    Table 38. Asia Pacific Targeting p53 Cancer Therapies Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific Targeting p53 Cancer Therapies Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Targeting p53 Cancer Therapies Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America Targeting p53 Cancer Therapies Sales by Country (2018-2023) & (K Units)
    Table 42. Latin America Targeting p53 Cancer Therapies Sales by Country (2024-2029) & (K Units)
    Table 43. Latin America Targeting p53 Cancer Therapies Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Targeting p53 Cancer Therapies Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Targeting p53 Cancer Therapies Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa Targeting p53 Cancer Therapies Sales by Country (2018-2023) & (K Units)
    Table 47. Middle East & Africa Targeting p53 Cancer Therapies Sales by Country (2024-2029) & (K Units)
    Table 48. Middle East & Africa Targeting p53 Cancer Therapies Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Targeting p53 Cancer Therapies Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global Targeting p53 Cancer Therapies Sales (K Units) by Type (2018-2023)
    Table 51. Global Targeting p53 Cancer Therapies Sales (K Units) by Type (2024-2029)
    Table 52. Global Targeting p53 Cancer Therapies Sales Market Share by Type (2018-2023)
    Table 53. Global Targeting p53 Cancer Therapies Sales Market Share by Type (2024-2029)
    Table 54. Global Targeting p53 Cancer Therapies Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global Targeting p53 Cancer Therapies Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2018-2023)
    Table 57. Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2024-2029)
    Table 58. Global Targeting p53 Cancer Therapies Price (US$/Unit) by Type (2018-2023)
    Table 59. Global Targeting p53 Cancer Therapies Price (US$/Unit) by Type (2024-2029)
    Table 60. Global Targeting p53 Cancer Therapies Sales (K Units) by Application (2018-2023)
    Table 61. Global Targeting p53 Cancer Therapies Sales (K Units) by Application (2024-2029)
    Table 62. Global Targeting p53 Cancer Therapies Sales Market Share by Application (2018-2023)
    Table 63. Global Targeting p53 Cancer Therapies Sales Market Share by Application (2024-2029)
    Table 64. Global Targeting p53 Cancer Therapies Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global Targeting p53 Cancer Therapies Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2018-2023)
    Table 67. Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2024-2029)
    Table 68. Global Targeting p53 Cancer Therapies Price (US$/Unit) by Application (2018-2023)
    Table 69. Global Targeting p53 Cancer Therapies Price (US$/Unit) by Application (2024-2029)
    Table 70. Sibiono GeneTech Corporation Information
    Table 71. Sibiono GeneTech Description and Business Overview
    Table 72. Sibiono GeneTech Targeting p53 Cancer Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 73. Sibiono GeneTech Targeting p53 Cancer Therapies Product
    Table 74. Sibiono GeneTech Recent Developments/Updates
    Table 75. Kartos Therapeutics Corporation Information
    Table 76. Kartos Therapeutics Description and Business Overview
    Table 77. Kartos Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 78. Kartos Therapeutics Targeting p53 Cancer Therapies Product
    Table 79. Kartos Therapeutics Recent Developments/Updates
    Table 80. SynerGene Therapeutics Corporation Information
    Table 81. SynerGene Therapeutics Description and Business Overview
    Table 82. SynerGene Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 83. SynerGene Therapeutics Targeting p53 Cancer Therapies Product
    Table 84. SynerGene Therapeutics Recent Developments/Updates
    Table 85. MultiVir Corporation Information
    Table 86. MultiVir Description and Business Overview
    Table 87. MultiVir Targeting p53 Cancer Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 88. MultiVir Targeting p53 Cancer Therapies Product
    Table 89. MultiVir Recent Developments/Updates
    Table 90. Rain Oncology Corporation Information
    Table 91. Rain Oncology Description and Business Overview
    Table 92. Rain Oncology Targeting p53 Cancer Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 93. Rain Oncology Targeting p53 Cancer Therapies Product
    Table 94. Rain Oncology Recent Developments/Updates
    Table 95. Alieron Therapeutics Corporation Information
    Table 96. Alieron Therapeutics Description and Business Overview
    Table 97. Alieron Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 98. Alieron Therapeutics Targeting p53 Cancer Therapies Product
    Table 99. Alieron Therapeutics Recent Developments/Updates
    Table 100. Aprea Therapeutics Corporation Information
    Table 101. Aprea Therapeutics Description and Business Overview
    Table 102. Aprea Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 103. Aprea Therapeutics Targeting p53 Cancer Therapies Product
    Table 104. Aprea Therapeutics Recent Developments/Updates
    Table 105. Ascentage Pharma Corporation Information
    Table 106. Ascentage Pharma Description and Business Overview
    Table 107. Ascentage Pharma Targeting p53 Cancer Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 108. Ascentage Pharma Targeting p53 Cancer Therapies Product
    Table 109. Ascentage Pharma Recent Developments/Updates
    Table 110. Jc (Wuxi) Company Corporation Information
    Table 111. Jc (Wuxi) Company Description and Business Overview
    Table 112. Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 113. Jc (Wuxi) Company Targeting p53 Cancer Therapies Product
    Table 114. Jc (Wuxi) Company Recent Developments/Updates
    Table 115. Key Raw Materials Lists
    Table 116. Raw Materials Key Suppliers Lists
    Table 117. Targeting p53 Cancer Therapies Distributors List
    Table 118. Targeting p53 Cancer Therapies Customers List
    Table 119. Targeting p53 Cancer Therapies Market Trends
    Table 120. Targeting p53 Cancer Therapies Market Drivers
    Table 121. Targeting p53 Cancer Therapies Market Challenges
    Table 122. Targeting p53 Cancer Therapies Market Restraints
    Table 123. Research Programs/Design for This Report
    Table 124. Key Data Information from Secondary Sources
    Table 125. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Targeting p53 Cancer Therapies
    Figure 2. Global Targeting p53 Cancer Therapies Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global Targeting p53 Cancer Therapies Market Share by Type in 2022 & 2029
    Figure 4. Small Molecule Drugs Product Picture
    Figure 5. Immunotherapy Product Picture
    Figure 6. Gene Therapy Product Picture
    Figure 7. Others Product Picture
    Figure 8. Global Targeting p53 Cancer Therapies Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 9. Global Targeting p53 Cancer Therapies Market Share by Application in 2022 & 2029
    Figure 10. Hospital
    Figure 11. Clinic
    Figure 12. Others
    Figure 13. Global Targeting p53 Cancer Therapies Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 14. Global Targeting p53 Cancer Therapies Market Size (2018-2029) & (US$ Million)
    Figure 15. Global Targeting p53 Cancer Therapies Sales (2018-2029) & (K Units)
    Figure 16. Global Targeting p53 Cancer Therapies Average Price (US$/Unit) & (2018-2029)
    Figure 17. Targeting p53 Cancer Therapies Report Years Considered
    Figure 18. Targeting p53 Cancer Therapies Sales Share by Manufacturers in 2022
    Figure 19. Global Targeting p53 Cancer Therapies Revenue Share by Manufacturers in 2022
    Figure 20. The Global 5 and 10 Largest Targeting p53 Cancer Therapies Players: Market Share by Revenue in 2022
    Figure 21. Targeting p53 Cancer Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 22. Global Targeting p53 Cancer Therapies Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 23. North America Targeting p53 Cancer Therapies Sales Market Share by Country (2018-2029)
    Figure 24. North America Targeting p53 Cancer Therapies Revenue Market Share by Country (2018-2029)
    Figure 25. United States Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 26. Canada Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 27. Europe Targeting p53 Cancer Therapies Sales Market Share by Country (2018-2029)
    Figure 28. Europe Targeting p53 Cancer Therapies Revenue Market Share by Country (2018-2029)
    Figure 29. Germany Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 30. France Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 31. U.K. Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 32. Italy Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 33. Russia Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 34. Asia Pacific Targeting p53 Cancer Therapies Sales Market Share by Region (2018-2029)
    Figure 35. Asia Pacific Targeting p53 Cancer Therapies Revenue Market Share by Region (2018-2029)
    Figure 36. China Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 37. Japan Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 38. South Korea Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 39. India Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. Australia Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 41. China Taiwan Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 42. Southeast Asia Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 43. Latin America Targeting p53 Cancer Therapies Sales Market Share by Country (2018-2029)
    Figure 44. Latin America Targeting p53 Cancer Therapies Revenue Market Share by Country (2018-2029)
    Figure 45. Mexico Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 46. Brazil Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 47. Argentina Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 48. Middle East & Africa Targeting p53 Cancer Therapies Sales Market Share by Country (2018-2029)
    Figure 49. Middle East & Africa Targeting p53 Cancer Therapies Revenue Market Share by Country (2018-2029)
    Figure 50. Turkey Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 51. Saudi Arabia Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 52. UAE Targeting p53 Cancer Therapies Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 53. Global Sales Market Share of Targeting p53 Cancer Therapies by Type (2018-2029)
    Figure 54. Global Revenue Market Share of Targeting p53 Cancer Therapies by Type (2018-2029)
    Figure 55. Global Targeting p53 Cancer Therapies Price (US$/Unit) by Type (2018-2029)
    Figure 56. Global Sales Market Share of Targeting p53 Cancer Therapies by Application (2018-2029)
    Figure 57. Global Revenue Market Share of Targeting p53 Cancer Therapies by Application (2018-2029)
    Figure 58. Global Targeting p53 Cancer Therapies Price (US$/Unit) by Application (2018-2029)
    Figure 59. Targeting p53 Cancer Therapies Value Chain
    Figure 60. Targeting p53 Cancer Therapies Production Process
    Figure 61. Channels of Distribution (Direct Vs Distribution)
    Figure 62. Distributors Profiles
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed

The essence of p53-targeted therapy is to regain the "tumor suppressor function" of the mutated p53 protein, or indirectly protect the "tumor suppressor function" of p53 by inhibiting other targets that can inhibit the wild-type p53 protein.

According to QYResearch’s new survey, global Targeting p53 Cancer Therapies market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Targeting p53 Cancer Therapies market research.

Key manufacturers engaged in the Targeting p53 Cancer Therapies industry include Sibiono GeneTech, Kartos Therapeutics, SynerGene Therapeutics, MultiVir, Rain Oncology, Alieron Therapeutics, Aprea Therapeutics, Ascentage Pharma and Jc (Wuxi) Company, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Targeting p53 Cancer Therapies were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Targeting p53 Cancer Therapies market and estimated to attract more attentions from industry insiders and investors.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Targeting p53 Cancer Therapies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
    Sibiono GeneTech
    Kartos Therapeutics
    SynerGene Therapeutics
    MultiVir
    Rain Oncology
    Alieron Therapeutics
    Aprea Therapeutics
    Ascentage Pharma
    Jc (Wuxi) Company

Segment by Type
    Small Molecule Drugs
    Immunotherapy
    Gene Therapy
    Others

Segment by Application
    Hospital
    Clinic
    Others

Consumption by Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Southeast Asia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

The Targeting p53 Cancer Therapies report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source